Sintilimab
- Generic Name
- Sintilimab
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 2072873-06-2
- Unique Ingredient Identifier
- 8FU7FQ8UPK
- Associated Conditions
- -
- Associated Therapies
- -
Surufatinib and Sintilimab in Combination With Capecitabine for Metastatic Adenocarcinoma of Small Intestine or Appendix Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-07-25
- Last Posted Date
- 2023-02-28
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 36
- Registration Number
- NCT05472948
- Locations
- 🇨🇳
The Sixth Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong, China
Anti-PD-1 Antibody Combined With Autologous DC and NK Cells in the Treatment of Digestive Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-07-18
- Last Posted Date
- 2022-07-18
- Lead Sponsor
- China Medical University, China
- Target Recruit Count
- 1
- Registration Number
- NCT05461235
Neoadjuvant Chemoradiotherapy Plus Sintilimab for Intermediate/High Immunoscore Locally Advanced Rectal Cancer
- First Posted Date
- 2022-07-08
- Last Posted Date
- 2023-09-26
- Lead Sponsor
- Yanhong Deng
- Target Recruit Count
- 51
- Registration Number
- NCT05450029
- Locations
- 🇨🇳
Department of colorectal surgery, the Sixth Affiliated Hospital, Sun Yat-Sen University, Guangzhou, Guangdong, China
Study of Intratumoral IVX037 in Patients With Advanced or Metastatic Solid Tumours
- Conditions
- Interventions
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2024-10-31
- Lead Sponsor
- ImmVirx Pty Ltd
- Target Recruit Count
- 70
- Registration Number
- NCT05427487
- Locations
- 🇦🇺
The Austin Hospital, Melbourne, Victoria, Australia
🇦🇺Western Health - Sunshine Hospital, Melbourne, Victoria, Australia
🇦🇺St Vincent's Hospital Sydney, Sydney, New South Wales, Australia
Sintilimab and Bevacizumab Biosimilar Combined With PLD in mTNBC
- Conditions
- Interventions
- First Posted Date
- 2022-05-23
- Last Posted Date
- 2023-02-16
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 41
- Registration Number
- NCT05386524
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Afuresertib +Sintilimab+Chemotherapy in Patients With Selected Solid Tumors That Resistance to Prior Anti-PD-1/PD-L1
- Conditions
- Interventions
- First Posted Date
- 2022-05-20
- Last Posted Date
- 2024-10-14
- Lead Sponsor
- Laekna Limited
- Target Recruit Count
- 167
- Registration Number
- NCT05383482
- Locations
- 🇨🇳
Zhongshan Hospital, Fudan University, Shanghai, Shanghai, China
🇨🇳Beijing Cancer Hospital, Beijing, Beijing, China
🇨🇳Chongqing Cancer Hospital, Chongqing, Chengdu, China
A Clinical Study to Observe the Effectiveness and Safety of IBI310, Bevacizumab Combined With Sintilimab in the Treatment of Advanced Hepatocellular Carcinoma
- Conditions
- Interventions
- First Posted Date
- 2022-05-06
- Last Posted Date
- 2022-05-06
- Lead Sponsor
- Shanghai Zhongshan Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT05363722
PD-1 Inhibitor Combined With Neoadjuvant Chemoradiotherapy Plus Surgery for Locally Advanced ESCC (NEOCRTEC2101)
- First Posted Date
- 2022-05-03
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- Sun Yat-sen University
- Target Recruit Count
- 422
- Registration Number
- NCT05357846
- Locations
- 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China
IMRT Plus PD-1 Blockade and Lenvatinib for HCC With PVTT (Vp3) Before Liver Transplantation
- Conditions
- Interventions
- First Posted Date
- 2022-04-21
- Last Posted Date
- 2022-04-27
- Lead Sponsor
- RenJi Hospital
- Target Recruit Count
- 78
- Registration Number
- NCT05339581
- Locations
- 🇨🇳
Ren Ji Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
Sintilimab Combined With Anlotinib Therapy for Initially Unresectable Non-small Cell Lung Cancer
- Conditions
- Interventions
- First Posted Date
- 2022-04-01
- Last Posted Date
- 2022-04-01
- Lead Sponsor
- Peking Union Medical College Hospital
- Target Recruit Count
- 93
- Registration Number
- NCT05306847
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.